vs
UiPath, Inc.（PATH）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是UiPath, Inc.的1.9倍（$790.2M vs $411.1M），UiPath, Inc.净利率更高（48.4% vs 46.1%，领先2.3%），UiPath, Inc.同比增速更快（15.9% vs 7.4%），UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $25.1M），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs 0.7%）
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
PATH vs UTHR — 直观对比
营收规模更大
UTHR
是对方的1.9倍
$411.1M
营收增速更快
PATH
高出8.5%
7.4%
净利率更高
PATH
高出2.3%
46.1%
自由现金流更多
UTHR
多$148.2M
$25.1M
两年增速更快
UTHR
近两年复合增速
0.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.1M | $790.2M |
| 净利润 | $198.8M | $364.3M |
| 毛利率 | 83.3% | 86.9% |
| 营业利润率 | 3.2% | 45.1% |
| 净利率 | 48.4% | 46.1% |
| 营收同比 | 15.9% | 7.4% |
| 净利润同比 | 1966.2% | 20.9% |
| 每股收益（稀释后） | $0.37 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PATHUTHR
| Q4 25 | $411.1M | $790.2M | ||
| Q3 25 | $361.7M | $799.5M | ||
| Q2 25 | $356.6M | $798.6M | ||
| Q1 25 | $423.6M | $794.4M | ||
| Q4 24 | $354.7M | $735.9M | ||
| Q3 24 | $316.3M | $748.9M | ||
| Q2 24 | $335.1M | $714.9M | ||
| Q1 24 | $405.3M | $677.7M |
净利润PATHUTHR
| Q4 25 | $198.8M | $364.3M | ||
| Q3 25 | $1.6M | $338.7M | ||
| Q2 25 | $-22.6M | $309.5M | ||
| Q1 25 | $51.8M | $322.2M | ||
| Q4 24 | $-10.7M | $301.3M | ||
| Q3 24 | $-86.1M | $309.1M | ||
| Q2 24 | $-28.7M | $278.1M | ||
| Q1 24 | $33.9M | $306.6M |
毛利率PATHUTHR
| Q4 25 | 83.3% | 86.9% | ||
| Q3 25 | 82.2% | 87.4% | ||
| Q2 25 | 82.1% | 89.0% | ||
| Q1 25 | 84.8% | 88.4% | ||
| Q4 24 | 82.0% | 89.7% | ||
| Q3 24 | 80.0% | 88.9% | ||
| Q2 24 | 83.5% | 89.1% | ||
| Q1 24 | 86.8% | 89.2% |
营业利润率PATHUTHR
| Q4 25 | 3.2% | 45.1% | ||
| Q3 25 | -5.6% | 48.6% | ||
| Q2 25 | -4.6% | 45.6% | ||
| Q1 25 | 7.9% | 48.2% | ||
| Q4 24 | -12.2% | 48.6% | ||
| Q3 24 | -32.7% | 45.8% | ||
| Q2 24 | -14.8% | 44.7% | ||
| Q1 24 | 3.7% | 52.6% |
净利率PATHUTHR
| Q4 25 | 48.4% | 46.1% | ||
| Q3 25 | 0.4% | 42.4% | ||
| Q2 25 | -6.3% | 38.8% | ||
| Q1 25 | 12.2% | 40.6% | ||
| Q4 24 | -3.0% | 40.9% | ||
| Q3 24 | -27.2% | 41.3% | ||
| Q2 24 | -8.6% | 38.9% | ||
| Q1 24 | 8.4% | 45.2% |
每股收益（稀释后）PATHUTHR
| Q4 25 | $0.37 | $7.66 | ||
| Q3 25 | $0.00 | $7.16 | ||
| Q2 25 | $-0.04 | $6.41 | ||
| Q1 25 | $0.09 | $6.63 | ||
| Q4 24 | $-0.02 | $6.23 | ||
| Q3 24 | $-0.15 | $6.39 | ||
| Q2 24 | $-0.05 | $5.85 | ||
| Q1 24 | $0.07 | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $7.1B |
| 总资产 | $2.9B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PATHUTHR
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.8B | ||
| Q2 25 | $1.6B | $3.0B | ||
| Q1 25 | $1.6B | $3.3B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.7B | $3.3B | ||
| Q2 24 | $1.9B | $3.0B | ||
| Q1 24 | $1.9B | $2.7B |
股东权益PATHUTHR
| Q4 25 | $1.9B | $7.1B | ||
| Q3 25 | $1.7B | $6.6B | ||
| Q2 25 | $1.7B | $7.2B | ||
| Q1 25 | $1.8B | $6.8B | ||
| Q4 24 | $1.7B | $6.4B | ||
| Q3 24 | $1.8B | $6.1B | ||
| Q2 24 | $2.0B | $5.7B | ||
| Q1 24 | $2.0B | $5.3B |
总资产PATHUTHR
| Q4 25 | $2.9B | $7.9B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.9B | ||
| Q1 25 | $2.9B | $7.7B | ||
| Q4 24 | $2.7B | $7.4B | ||
| Q3 24 | $2.7B | $7.1B | ||
| Q2 24 | $2.8B | $6.7B | ||
| Q1 24 | $3.0B | $6.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $25.1M | $173.3M |
| 自由现金流率自由现金流/营收 | 6.1% | 21.9% |
| 资本支出强度资本支出/营收 | 0.8% | 21.9% |
| 现金转化率经营现金流/净利润 | 0.14× | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流PATHUTHR
| Q4 25 | $28.3M | $346.2M | ||
| Q3 25 | $41.6M | $562.1M | ||
| Q2 25 | $119.0M | $191.7M | ||
| Q1 25 | $146.1M | $461.2M | ||
| Q4 24 | $28.1M | $341.2M | ||
| Q3 24 | $46.4M | $377.2M | ||
| Q2 24 | $100.0M | $232.2M | ||
| Q1 24 | $145.6M | $376.5M |
自由现金流PATHUTHR
| Q4 25 | $25.1M | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | $106.2M | $129.5M | ||
| Q1 25 | $138.7M | $386.3M | ||
| Q4 24 | $23.2M | $254.5M | ||
| Q3 24 | $45.0M | $300.7M | ||
| Q2 24 | $98.8M | $187.1M | ||
| Q1 24 | $141.8M | $338.3M |
自由现金流率PATHUTHR
| Q4 25 | 6.1% | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | 29.8% | 16.2% | ||
| Q1 25 | 32.7% | 48.6% | ||
| Q4 24 | 6.5% | 34.6% | ||
| Q3 24 | 14.2% | 40.2% | ||
| Q2 24 | 29.5% | 26.2% | ||
| Q1 24 | 35.0% | 49.9% |
资本支出强度PATHUTHR
| Q4 25 | 0.8% | 21.9% | ||
| Q3 25 | 0.0% | 26.3% | ||
| Q2 25 | 3.6% | 7.8% | ||
| Q1 25 | 1.7% | 9.4% | ||
| Q4 24 | 1.4% | 11.8% | ||
| Q3 24 | 0.4% | 10.2% | ||
| Q2 24 | 0.4% | 6.3% | ||
| Q1 24 | 0.9% | 5.6% |
现金转化率PATHUTHR
| Q4 25 | 0.14× | 0.95× | ||
| Q3 25 | 26.25× | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | 2.82× | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | 4.29× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
